Last reviewed · How we verify
GP40081
GP40081 is a small molecule drug that targets the sigma-1 receptor.
GP40081 is a small molecule drug that targets the sigma-1 receptor. Used for Treatment-resistant depression.
At a glance
| Generic name | GP40081 |
|---|---|
| Also known as | Insulin aspart 30 mix |
| Sponsor | Geropharm |
| Drug class | sigma-1 receptor modulator |
| Target | sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Sigma-1 receptors are involved in various cellular processes, including neuroprotection and inflammation. GP40081 is being investigated for its potential therapeutic effects in conditions where sigma-1 receptor modulation may be beneficial.
Approved indications
- Treatment-resistant depression
Common side effects
- Dizziness
Key clinical trials
- Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP40081 CI brief — competitive landscape report
- GP40081 updates RSS · CI watch RSS
- Geropharm portfolio CI